Drug Combination Details
| General Information of the Combination (ID: C97410) | |||||
|---|---|---|---|---|---|
| Name | Thymoquinone NP Info | + | Difluoromethylornithine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Anaplastic large cell lymphoma
[ICD-11: 2A90]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | DNMT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | HDAC1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | UHRF1 | Molecule Info | |||
| In-vitro Model | Jurkat | CVCL_0065 | T acute lymphoblastic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Thymoquinone and difluoromethylornithine (DFMO) synergistically induce apoptosis of human acute T lymphoblastic leukemia jurkat cells through the modulation of epigenetic pathways. | |||||
